Patents Assigned to Progen Co., Ltd.
  • Patent number: 11339197
    Abstract: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 24, 2022
    Assignee: PROGEN CO., LTD.
    Inventors: Zungyoon Yang, Eun Joo Nam
  • Publication number: 20210188931
    Abstract: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
    Type: Application
    Filed: October 23, 2018
    Publication date: June 24, 2021
    Applicant: PROGEN CO., LTD.
    Inventors: Zungyoon YANG, Eun Joo NAM
  • Patent number: 11001620
    Abstract: The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 11, 2021
    Assignee: PROGEN CO., LTD.
    Inventors: Young Chul Sung, Zungyoon Yang
  • Publication number: 20190062396
    Abstract: The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.
    Type: Application
    Filed: November 4, 2016
    Publication date: February 28, 2019
    Applicants: GENEXINE, INC., PROGEN CO., LTD.
    Inventors: Young Chul SUNG, Zungyoon YANG
  • Publication number: 20060223144
    Abstract: The present invention relates to a method for mass-production of human follicle stimulating hormone, more precisely, to an expression vector containing human follicle stimulating hormone gene, a transformant transfected with the expression vector and a method for mass-production of human follicle stimulating hormone by using the same. Human follicle stimulating hormone can be produced largely by using an expression vector and a transformant of the present invention. Therefore the expression vector and the transformant of the present invention can be effectively used for the treatment of infertility.
    Type: Application
    Filed: September 24, 2004
    Publication date: October 5, 2006
    Applicant: Progen Co., Ltd.
    Inventors: Se Hwan Yang, Young Chul Sung, Kyu-Heum Na, Sung Hee Lee, Won Bae Kim